European Companies Search Engine
EU funding (€3,971,460): Targeting Cartilage Regeneration in joint and intervertebral disc diseases Hor 1 Mar 2015 EU Research and Innovation programme "Horizon"
Overview
Text
Targeting Cartilage Regeneration in joint and intervertebral disc diseases
Mobility, important for well-being, is seriously impaired by chronic low back pain and osteoarthritis in many people due to degeneration of cartilaginous tissue of the intervertebral disc and joint. To develop a treatment for these diseases this ETN aims to combine expertise in novel highly advanced drug delivery carriers with dedicated targeting tools, state of the art imaging techniques and expertise in stem cell and joint biology by training 15 young scientists in 12 partner institutes located in 5 different countries. We aim to achieve regeneration of damaged and degenerated tissues by employing targeting strategies tailored both to the pathology and the tissues involved. Regeneration of diseased tissues will be achieved by loading biologically active agents in state-of-the-art nanocarriers. The biologically active agents will stimulate the body’s own capacity to regenerate by attracting local stem cells or inhibit degeneration. Targeting will be achieved by A] injection with synthetic or natural hydrogels loaded with the nanocarriers or B] coupling diseased tissue-specific antibodies and specific hyaluronic acid moieties to the nanocarriers. Delivery and retention will be monitored by advanced in vivo and molecular imaging techniques to monitor distribution of the delivered compounds at the tissue level, as well as detect biological markers of regeneration. Major objectives: 1] To establish a network of scientists skilled in the use of smart nanocarriers, unique approach of targeting by disease-specific molecules and application of innovative imaging tools. Supported by generic scientific and training in economical and clinical valorisation, these researchers can further implement these technologies in the musculoskeletal or other areas, both in academia and industry. 2] To develop strategies exclusively targeting diseased tissues with controlled doses of bio-actives, circumventing the disadvantages of the current shotgun approaches in regenerative medicine.
Funded Companies:
| Company name | Funding amount |
| Omics2Image B.V. | ? |
| Aarhus Universitet | €290,082 |
| Cardiff University | €273,288 |
| Erasmus Universitair Medisch Centrum Rotterdam | €510,749 |
| Imperial College of Science Technology and Medicine | €546,576 |
| Percuros B.V. | €255,374 |
| Procore Ltd. | €260,301 |
| Technion - Israel Institute OF Technology | €520,601 |
| The University Court of the University of Aberdeen | €273,288 |
| Universitair Medisch Centrum Utrecht | €255,374 |
| Universiteit Maastricht | €255,374 |
| АО Forschungsinstitut Davos | €530,454 |
Source: https://cordis.europa.eu/project/id/642414
The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: Omics2Image B.V., Maastricht, Netherlands.
